|
Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States Clinical research trials and Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States. Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States clinical trial. Test subjects typically obtain the finest healthcare available for their Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States  Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States
Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States
For Condition: Herpesviridae Infection,Kaposi's Sarcoma
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will investigate patterns of Kaposi's sarcoma herpes virus (KSHV) in the United States and its potential impact on the U.S. population. KSHV is a newly discovered virus that is strongly associated with Kaposi's sarcoma and primary effusion lymphoma. The high prevalence of KS and KSHV among HIV-infected homosexual men suggests sexual contact as a primary mode of transmission. Reports of non-sexual transmission in parts of Africa and the Mediterranean where Kaposi's sarcoma is endemic, and the identification of viral DNA in saliva and other bodily fluids, however, indicate the virus is also transmitted non-sexually. This study will: - Compare the prevalence of KSHV among different demographic groups in the United States - Examine the association between KSHV and high risk behaviors such as drug use (marijuana and cocaine), sexual behavior (age at first sexual intercourse and number of sexual partners), and medical risk factors (herpes simplex virus II, hepatitis B and hepatitis C) - Estimate the prevalence of KSHV in the United States. Data and blood samples for the study will be taken from the NHANES III survey. NHANES is a program of periodic surveys conducted by the Centers for Disease Control and Prevention's National Center for Health Statistics. The survey is designed to provide national estimates of health status for the United States non-institutionalized civilian population by means of household interviews, standardized physical examinations, and blood sample collection and testing. NHANES III-the seventh in a series of national examination studies-was conducted from 1988 to 1994. This study will use the HANES data to identify risks associated with a KSHV-positive blood test in the survey population. The study plans to include all 19,754 participants (67% of the 29,314 participants originally examined) for whom blood samples were collected and remain available.
Details: The primary mission of the Viral Epidemiology Branch is to investigate the role of viruses and other infectious agents in the etiology of human cancer. Data from national and international sources are used to generate hypotheses regarding cancer etiology with an emphasis on patterns suggesting an infectious process. One major focus of VEB research is Kaposi's Sarcoma Herpes Virus (KSHV or human herpesvirus type 8), a newly discovered virus that is strongly associated with Kaposi's sarcoma (KS) and primary effusion lymphoma. A high prevalence of KS and KSHV among HIV-infected homosexual men in the US and other Northern European countries suggest the primary mode of transmission for the virus is sexual. However, non-sexual transmission has been reported in KS endemic areas such as parts of Africa and the Mediterranean, and KSHV DNA has been identified in saliva and other bodily fluids. These reports suggest non-sexual transmission of the virus must occur. To further investigate patterns of KSHV infection in the US and its potential impact on the US population we propose to use data and sera from a population-based survey to: 1) examine the association between KSHV seropositivity and selected sociodemographic characteristics and medical risk factors, and 2) estimate the seroprevalence of KSHV in the US population.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No specific eligibility criteria was provided for this protocol.
Total Enrollment: 20169
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 010073; 01-C-0073
Study Start Date: February 12, 2001
Record last reviewed: January 6, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00026728
Other Herpesviridae Infection Studies:
1. Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer
2. Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
3. Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
4. A Phase II Study of Oral Thalidomide for Patients with HIV Infection and Kaposi's Sarcoma
5. Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
Related Studies:
Other Herpesviridae Infection Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States
|
|
|
|
|
|
|
|
